Creative Medical Technology (NASDAQ:CELZ) Trading Up 3% – What’s Next?

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ)’s stock price shot up 3% during mid-day trading on Monday . The company traded as high as $2.11 and last traded at $2.08. 25,616 shares traded hands during trading, a decline of 82% from the average session volume of 145,977 shares. The stock had previously closed at $2.02.

Analyst Ratings Changes

Several equities research analysts have weighed in on CELZ shares. Wall Street Zen cut Creative Medical Technology from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Creative Medical Technology in a research note on Monday, December 29th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce”.

Creative Medical Technology Stock Up 3.0%

The company has a market capitalization of $5.37 million, a PE ratio of -0.71 and a beta of 2.08. The company’s 50 day moving average is $2.16 and its two-hundred day moving average is $2.89.

Creative Medical Technology (NASDAQ:CELZ) last announced its quarterly earnings results on Friday, November 7th. The company reported ($0.48) earnings per share for the quarter, hitting the consensus estimate of ($0.48). Analysts forecast that Creative Medical Technology Holdings, Inc. will post -3.19 EPS for the current year.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.